MedCity News

MARCH 28, 2025

Medicaid and SNAP cuts could lead to 1 million jobs lost in just 2026, according to a new report from the Commonwealth Fund and the George Washington University Milken Institute School of Public Health. The post Report: How Medicaid/SNAP Cuts Could Affect the Economy appeared first on MedCity News.

Leads 272

Leads 272

MedCity News

OCTOBER 3, 2024

The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE.

Biopharma 315

Biopharma Pharma 315

MedCity News

MAY 15, 2023

The royalty deal extends uniQure’s cash runway into 2026. By selling partial royalties to approved hemophilia gene therapy Hemgenix, uniQure gains immediate cash to support its pipeline, including a Huntington’s disease gene therapy already in the clinic.

Biopharma 290

Biopharma Pharma 290

PharmaVoice

OCTOBER 23, 2024

As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.

246

246

Fierce Pharma

OCTOBER 30, 2024

Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects.

Prospecting 214

Prospecting Medicine FDA 214

pharmaphorum

OCTOBER 24, 2024

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its recently announced $2.6 billion takeover of Longboard Pharma.

Pharma 106

Pharma 106

Fierce Pharma

SEPTEMBER 7, 2023

Now that the Centers for Medicare & Medicaid Services (CMS) has revealed its li | Now that the CMS has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act, it’s time to consider the financial implications for affected companies.

206

206

European Pharmaceutical Review

SEPTEMBER 12, 2023

Over 50 percent of respondents answered that machine learning for optimisation of manufacturing processes will be the technology that will be used routinely in the pharmaceutical industry by 2026. The post AI to revolutionise drug development by 2026 appeared first on European Pharmaceutical Review.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Pharmaceutical FDA 105

pharmaphorum

NOVEMBER 12, 2024

AstraZeneca plans to invest a whopping $3.5

Biopharma 98

Biopharma Sales Manufacturing Pharma 98

European Pharmaceutical Review

AUGUST 19, 2022

billion by 2026. percent between 2021 and 2026 (the forecast period). Billion by 2026, achieving a 5.6 billion by 2026, as contract manufacturing organisations increasingly adopt newer and efficient ways to package products, increasing demand for new machinery. billion by the year 2026. Within the $130.2

Manufacturing 98

Manufacturing Marketing Pharma Pharmaceutical 98

Fierce Pharma

SEPTEMBER 28, 2023

Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business. Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business.

Sales 203

Sales 203

PharmaVoice

MARCH 11, 2025

Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

180

180

Fierce Pharma

SEPTEMBER 5, 2023

The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.

Biopharma 266

Biopharma Government 266

Fierce Pharma

SEPTEMBER 12, 2023

28, 2026. The deal clears “all pending claims” and tees up a potential Dasynoc launch on Sept. 1, 2024, or potentially earlier under certain circumstances. The Sprycel patents in question aren’t due to expire until Sept.

FDA 262

FDA Pharma 262

Fierce Pharma

OCTOBER 9, 2023

billion) for exclusive rights to distribute the shingles shot in China from 2024 through 2026. GSK has forged a partnership with vaccine powerhouse Chongqing | GSK has forged a partnership with vaccine powerhouse Chongqing Zhifei Biological Products to distribute Shingrix in China. Zhifei will pay £2.5 billion ($3.05

Distribution 254

Distribution 254

Fierce Pharma

SEPTEMBER 3, 2024

28, 2026. Reddy’s formulations production plant, China’s National Medical Products Administration has suspended the import, sale and use of the Indian drugmaker’s atomoxetine hydrochloride capsules for ADHD. In addition, Dr. Reddy’s is prohibited from taking part in China’s drug procurement scheme through Feb.

Manufacturing 205

Manufacturing Sales Medical 205

Fierce Pharma

JANUARY 4, 2024

The Seattle-based CDMO has unveiled its plan to construct a four-story complex, which will cover 20,000 square meters (215,000 square feet) and is expected to become operational in 2026.

Manufacturing 227

Manufacturing 227

Fierce Pharma

MARCH 18, 2024

As bluebird bio works to make the most of three gene therapy launches, cash-flow concerns have been looming over the drugmaker. | The funding should extend bluebird bio's cash runway through the first quarter of 2026 as it advances three gene therapy launches.

209

209

Fierce Pharma

NOVEMBER 12, 2024

The cash will be used to grow the company’s research and production footprint in the States by the end of 2026, generating more than 1,000 new jobs along the way. . | AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total capital investment of $3.5

Manufacturing 189

Manufacturing 189

Fierce Pharma

JUNE 10, 2024

Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower prices on certain drugs starting in 2026. After the review board unanimously agreed that Stelara is "unaffordable," the drug could be subject to an upper payment limit in the state.

Prescription 189

Prescription Marketing 189

Fierce Pharma

OCTOBER 7, 2024

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.

Healthcare 184

Healthcare Healthcare 184

Fierce Pharma

OCTOBER 27, 2023

In August, Imbruvica was one of the 10 drugs identified by the CMS that will be subject to price negotiations in 2026. . | Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from BeiGene’s Brukinsa. But what about the impact of the Inflation Reduction Act?

Sales 215

Sales 215

MedCity News

FEBRUARY 12, 2025

Centivo and Premise Health are launching a new primary care-focused health plan that will become available to employers in the 2026 benefits cycle. The post Centivo, Premise Health Strike Partnership to Create Primary Care-Focused Health Plan appeared first on MedCity News.

166

166

PharmaVoice

AUGUST 16, 2024

The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.

148

148

Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

Sales 193

Sales 193

Fierce Pharma

DECEMBER 14, 2023

Ahead of 2026’s Medicare drug price negotiations, the White House is getting ready to crack down on companies who’ve raised the costs of their medications faster than the rate of inflation.

Medical 180

Medical 180

PharmaVoice

NOVEMBER 5, 2024

Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.

Marketing 130

Marketing 130

Pharmaceutical Technology

NOVEMBER 19, 2024

Regenxbio’s plans toward a BLA filing in 2026 after positive data from the Phase I/II AFINITY DUCHENNE trial.

52

52

pharmaphorum

MAY 3, 2024

AI-powered home healthcare model from Cera could save NHS and UK £1bn in 2026 if adopted nationwide, says new study

Healthcare 109

Healthcare Healthcare 109

World of DTC Marketing

MAY 9, 2022

Online Ad Stats : Social media advertising budgets are expected to grow 11.76% annually by 2026. billion by 2026 , is still a new frontier of the digital world, an all but lawless Wild West where a few major industry players have seized territory for their gain. Online ad fraud is costing pharma millions.

Pharma 208

Pharma Media Marketing Sales 208

Pharmaceutical Commerce

AUGUST 16, 2024

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

Medical 98

Medical 98

Pharmaceutical Technology

FEBRUARY 6, 2025

CagriSema, considered a successor to Wegovy, is Novo Nordisks most likely route of gaining GLP-1RA market share back from Eli Lilly.

Marketing 64

Marketing 64

Pharmacy Times

APRIL 2, 2025

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

49

49

Scott Burrows

JULY 5, 2022

By 2026, industry experts expect EV sales to quadruple from 2020,… As an insurance and financial speaker with strong ties to the industry, I have not seen such interesting—and positive—developments in years. For example, according to Statista the sales of electric vehicles are on the verge of explosion.

Insurance 98

Insurance Sales 98

Pharmaceutical Technology

APRIL 7, 2025

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of Americans.

52

52

European Pharmaceutical Review

NOVEMBER 12, 2024

To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 billion of capital investment in the US. Of this amount, $2 billion will generate over 1,000 new jobs, the company added.

Manufacturing 59

Manufacturing Biopharma Healthcare Healthcare 59

European Pharmaceutical Review

MARCH 17, 2025

billion investment in the US in November 2024, aligning with its aim to enhance its research and manufacturing footprint by the end of next 2026. AstraZenecas recent investments This news builds on AstraZenecas recent financial commitments, including in the US and Canada. The company announced a $3.5

Engineering 52

Engineering Manufacturing Patients Pharmaceutical 52